KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy (pages 1259–1265)
Emanuele Valtorta, Sandra Misale, Andrea Sartore-Bianchi, Iris D. Nagtegaal, François Paraf, Calogero Lauricella, Valentina Dimartino, Sebastijan Hobor, Bart Jacobs, Cristiana Ercolani, Simona Lamba, Elisa Scala, Silvio Veronese, Pierre Laurent-Puig, Salvatore Siena, Sabine Tejpar, Marcella Mottolese, Cornelis J.A. Punt, Marcello Gambacorta, Alberto Bardelli and Federica Di Nicolantonio
Article first published online: 16 MAR 2013 | DOI: 10.1002/ijc.28106
Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR) are one of the therapeutic options for metastatic colorectal cancer, but they are effective only in a small subset of patients. Here the authors determined the prevalence of KRAS gene amplification in a large dataset of colorectal cancer samples and assessed the possible predictive role of KRAS gene copy number status in response to anti-EGFR treatment. The data show that amplification of the KRAS oncogene occurs in a small fraction of KRAS wild-type cases and that KRAS amplification is causally associated with resistance to anti-EGFR treatment.